Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Zhitao, Ying"'
Autor:
Yanfei Liu, Lingyan Ping, Yuqin Song, Yongjing Tang, Wen Zheng, Weiping Liu, Zhitao Ying, Chen Zhang, Meng Wu, Feier Feng, Ningjing Lin, Meifeng Tu, Jun Zhu, Yan Xie
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Background Classical Hodgkin lymphoma (cHL) is a highly curable disease, while novel therapy is needed for refractory or relapsed (R/R) patients. This phase II trial aimed to evaluate the role of camrelizumab plus gemcitabine and oxaliplatin
Externí odkaz:
https://doaj.org/article/fa08cf055ddf4c60af21f800463a0902
Autor:
Ping Li, Yang Liu, Yun Liang, Jian Bo, Sujun Gao, Yongxian Hu, Yu Hu, He Huang, Xiaojun Huang, Hongmei Jing, Xiaoyan Ke, Jianyong Li, Yuhua Li, Qifa Liu, Peihua Lu, Heng Mei, Ting Niu, Yongping Song, Yuqin Song, Liping Su, Sanfang Tu, Jianxiang Wang, Depei Wu, Zhao Wang, Kailin Xu, Zhitao Ying, Qingming Yang, Yajing Zhang, Fengxia Shi, Bin Zhang, Huilai Zhang, Xi Zhang, Mingfeng Zhao, Weili Zhao, Xiangyu Zhao, Liang Huang, Jun Zhu, Wenbin Qian, Weidong Han, Aibin Liang
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 2, Pp 129-146 (2023)
Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in
Externí odkaz:
https://doaj.org/article/9444c9c2b3e5428698211ae089d3471a
Autor:
Yanfei Liu, Yuqin Song, Shubo Zuo, Xian Zhang, Hui Liu, Jingwen Wang, Jingbo Wang, Yongjing Tang, Wen Zheng, Zhitao Ying, Lingyan Ping, Chen Zhang, Meng Wu, Jun Zhu, Yan Xie
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe treatment for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) is suboptimal. This open-label, multicenter, single-arm study aimed to investigate the antitumor activity and safety of camrelizumab (a PD-1 blockade) plus apatin
Externí odkaz:
https://doaj.org/article/47f5da73004a4bf99dbec33371dabaaf
Autor:
Zhitao Ying, Haiyan Yang, Ye Guo, Wenyu Li, Dehui Zou, Daobin Zhou, Zhao Wang, Mingzhi Zhang, Jianqiu Wu, Hui Liu, Pian Zhang, Su Yang, Zisong Zhou, Hongxia Zheng, Yuqin Song, Jun Zhu
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 999-1011 (2021)
Abstract Background Despite numerous chimeric antigen receptor T‐cell (CAR‐T) trials conducted in China, no CAR‐T has been registered in the country. Furthermore, China law and regulations restrict the export of patient material for CAR‐T man
Externí odkaz:
https://doaj.org/article/13ad08ffbb1e4d2f8499a2bb859c0626
Autor:
Zhitao Ying, Ting He, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Chen Zhang, Weiping Liu, Lijuan Deng, Meng Wu, Feier Feng, Xin Leng, Tingting Du, Feifei Qi, Xuelian Hu, Yanping Ding, Xin-an Lu, Yuqin Song, Jun Zhu
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background The unprecedented efficacy of chimeric antigen receptor T (CAR-T) cell immunotherapy of CD19+ B-cell malignancies has opened a new and useful way for the treatment of malignant tumors. Nonetheless, there are still formidable chall
Externí odkaz:
https://doaj.org/article/921e55332f6c4de6b40c7b6e7c6cebc4
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades
Autor:
Weiping Liu, Xinqiang Ji, Yuqin Song, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Zhitao Ying, Chen Zhang, Lijuan Deng, Meng Wu, Feier Feng, Xin Leng, Yingli Sun, Tingting Du, Jun Zhu
Publikováno v:
Cancer Medicine, Vol 9, Iss 11, Pp 3765-3774 (2020)
Abstract Background The treatment outcomes and prognosis of lymphoma are affected by various factors such as hospital types. This study was to describe the temporal trend in the survival of lymphoma in an academic center in China. Methods A total of
Externí odkaz:
https://doaj.org/article/0df58d9410af481ea37a5eb1f5839b97
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Aim: To investigate the effectiveness and safety of using chimeric antigen receptor (CAR) T cell therapies targeting CD19 in patients with diffuse large B-cell lymphoma (DLBCL).Methods: PubMed, Embase, and the Cochrane Library were searched for repor
Externí odkaz:
https://doaj.org/article/bf12374719c74515bddd85a7e1b87dca
Autor:
Zhitao Ying, Ting He, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Chen Zhang, Weiping Liu, Lijuan Deng, Feifei Qi, Yanping Ding, Xin-an Lu, Yuqin Song, Jun Zhu
Publikováno v:
Molecular Therapy: Oncolytics, Vol 15, Iss , Pp 60-68 (2019)
CD19-targeted chimeric antigen receptor-T (CAR-T) cells with CD28 or 4-1BB (28z CAR-T and BBz CAR-T) have shown great promise to treat relapsed or refractory (r/r) B cell non-Hodgkin’s lymphoma (B-NHL). However, comparison of their clinical outcome
Externí odkaz:
https://doaj.org/article/1b15d082bdd240cdaca4890e9196767b
Autor:
Yalu Liu, Xiaogan Wang, Lijuan Deng, Lingyan Ping, Yunfei Shi, Wen Zheng, Ningjing Lin, Xiaopei Wang, Meifeng Tu, Yan Xie, Weiping Liu, Zhitao Ying, Chen Zhang, Zhengying Pan, Xi Wang, Ning Ding, Yuqin Song, Jun Zhu
Publikováno v:
Cancer Cell International, Vol 19, Iss 1, Pp 1-19 (2019)
Abstract Background Angioimmunoblastic T cell lymphoma (AITL) is a distinct subtype of peripheral T cell lymphoma and associated with poor outcomes. The activation status of T cell receptor (TCR) signaling has recently become a focus of attention in
Externí odkaz:
https://doaj.org/article/25c3629a1d384e438702a199c33a1a2e
Autor:
Yizi He, Jiao Li, Ning Ding, Xiaogan Wang, Lijuan Deng, Yan Xie, Zhitao Ying, Weiping Liu, Lingyan Ping, Chen Zhang, Yuqin Song, Jun Zhu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-16 (2019)
Abstract Background Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma. Although durable remissions can be achieved in more than half of these patients, DLBCL remains a significant clinical challenge, with approximately 30% of
Externí odkaz:
https://doaj.org/article/0c21c9711cd44ef292c51b467964b40d